A Feasibility Study Examining the Use of Non-Invasive Focused Ultrasound (FUS) with oral Etoposide Administration in Children with Progressive Diffuse Midline Glioma (DMG)
Study of Focused Ultrasound (FUS) with DEFINITY Microbubbles in Children and Young Adults with Progressive Diffuse Midline Glioma (DMG)
Sponsor: Conquer Cancer The ASCO Foundation and Focused Ultrasound Foundation
Enrolling: Male and Female Patients
IRB Number: AAAU1228
U.S. Govt. ID: NCT05762419
Contact: James Hinkley Garvin Jr, MD: / jhg1@cumc.columbia.edu
Additional Study Information: Children and young adults with diffuse midline glioma will be treated with Focused Ultrasound (FUS) with DEFINITY microbubbles and neuro-navigator-controlled sonication. The overall goal of this study is to see if the study treatment plan will improve the outcome of participants with diffuse midline glioma, for which no known cure exists, and determine whether there are any clinical benefits of the study treatment. Children with progressive diffuse midline gliomas (DMGs) have very poor outcomes and have very limited options. One of the main obstacles in the effectiveness of medical therapy in brain tumors is the presence of the Blood Brain Barrier (BBB). The BBB is a border between your brain and spine and the rest of your body that separates circulating blood from the brain and its fluid. The presence of the BBB prevents many drugs from reaching the brain and any tumors within it. However, studies have shown that the use of a focused ultrasound (FUS) along with intravenously administered DEFINITY microbubbles creates a targeted drug delivery system that may allow the drug to pass through the BBB and treat the tumor. Focused ultrasound is a non-invasive technique (meaning it does not cut the skin) used to open the blood-brain barrier temporarily along with the use of microbubbles. Once the BBB is open, subjects will be given Etoposide (an oral medication).
This study is closed
Investigator
James Hinkley Garvin Jr, MD
Do You Qualify?
Are you or your child between the ages of 4-39? Yes No
Do you/your child have a radiological or clinical diagnosis of Diffuse Midline Glioma? Yes No
Do you/your child have adequate organ function? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder




For more information, please contact:
James Hinkley Garvin Jr, MD
jhg1@cumc.columbia.edu